Abbott Laboratories filed a current report on July 16, 2026, reporting that it announced its results of operations for the second quarter of 2026 on the same date. The filing was made under Item 2.02, “Results of Operations and Financial Condition,” and incorporates by reference a July 16, 2026 press release furnished as Exhibit 99.1. The filing does not include the detailed financial figures from the press release in the provided document text, such as revenue, earnings per share, segment performance, or guidance. Instead, the 8-K primarily serves to notify investors that Abbott released its quarterly operating results and to explain the company’s use of non-GAAP financial measures in that announcement. Abbott said the earnings release uses several non-GAAP measures, including net earnings excluding specified items. The company stated that these adjustments are intended to exclude items it views as unusual, unpredictable, or not reflective of ongoing operations. Examples cited include expenses primarily associated with acquisitions, legal reserves, restructuring actions, certain regulatory costs, specified tax items, excess tax benefits tied to share-based compensation, and stock-based compensation expense from equity awards accelerated in connection with an acquisition. Abbott also noted that its non-GAAP measures exclude intangible amortization expense, saying this provides investors with greater visibility into operating results in a manner similar to how management internally evaluates performance. The company cautioned, however, that investors should consider these non-GAAP measures alongside, and not as substitutes for, financial results prepared under GAAP. The report was signed on behalf of Abbott Laboratories by Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer. The filing also lists Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.